Genome and epigenome wide studies of plasma protein biomarkers for Alzheimer’s disease implicate TBCA and TREM2 in disease risk - Hillary, Robert F.; Gadd, Danni A.; McCartney, Daniel L.; Shi, Liu; Campbell, Archie; Walker, Rosie M.; Ritchie, Craig W.; Deary, Ian J.; Evans, Kathryn L.; Nevado-Holgado, Alejo J.; Hayward, Caroline; Porteous, David J.; et al. (medRxiv, 2021)
The levels of many blood proteins are associated with Alzheimer’s disease or its pathological hallmarks. Elucidating the molecular factors that control circulating levels of these proteins may help to identify proteins causally associated with the disease. Here, genome-wide and epigenome-wide studies (nindividuals≤1,064) were performed on plasma levels of 281 Alzheimer’s disease-associated proteins, identified by a systematic review of the literature. We quantified the contributions of genetic and epigenetic variation towards inter-individual variability in plasma protein levels. Sixty-one independent genetic and 32 epigenetic loci were associated with expression levels of 49 proteins; eight and 24 of these respective findings are previously unreported. Novel findings included an association between plasma TREM2 levels and a polymorphism and CpG site within the MS4A4A locus. Through Mendelian randomisation analyses, causal associations were observed between higher plasma TBCA and TREM2 levels and lower Alzheimer’s disease risk. Our data inform the regulation of biomarker levels and their relationships with Alzheimer’s disease.Competing Interest StatementA.M.M has received research support from Eli Lilly, Janssen and the Sackler Foundation. A.M.M has also received speaker fees from Illumina and Janssen. S.L. is currently an employee of Johnson and Johnson Medical Ltd and previously received grant support from multiple pharmaceutical companies and the EU through the Innovation Medicines Initiative programmes EMIF and EPAD. R.E.M. has received speaker fees from Illumina and is an advisor to the Epigenetic Clock Development Foundation. The remaining authors declare that they have no competing interests.Funding StatementGeneration Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping and DNA methylation profiling of the Generation Scotland samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award ″STratifying Resilience and Depression Longitudinally″ ((STRADL) Reference [104036/Z/14/Z])). A.M.M is supported by Wellcome [104036/Z/14/Z, 216767/Z/19/Z, 220857/Z/20/Z], UKRI MRC [MC/PC/17209, MR/S035818/1] and the European Union H2020 [SEP/210574971]. R.F.H and D.A.G are supported by funding from the Wellcome four year PhD in Translational Neuroscience: training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. D.L.McC and R.E.M are supported by Alzheimer″s Research UK major project grant ARUK/PG2017B/10. Proteomic analyses in STRADL were supported by Dementias Platform UK (DPUK). DPUK funded this work through core grant support from the Medical Research Council [MR/L023784/2]. C.H. is supported by an MRC University Unit Programme Grant MC/UU/00007/10 (QTL in Health and Disease). L.S. is funded by DPUK through MRC [MR/L023784/2] and the UK Medical Research Council Award to the University of Oxford [MC/PC/17215]. L.S. received support from the NIHR Biomedical Research Centre at Oxford Health NHS Foundation Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All components of the Generation Scotland study received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Numbers: 05/S1401/89 and 10/S1402/20). All participants provided broad and enduring written informed consent for biomedical research. Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021). This study was performed in accordance with the Helsinki declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccording to the terms of consent for Generation Scotland participants, access to data must be reviewed by the Generation Scotland Access Committee. Applications should be made to access@generationscotland.org. All code is available at the following Github repository: https://github.com/robertfhillary/gwas_ewas_AD_plasma_biomarkers. https://github.com/robertfhillary/gwas_ewas_AD_plasma_biomarkers